These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27154916)

  • 1. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial.
    Xu R; Shimizu F; Hovinga K; Beal K; Karimi S; Droms L; Peck KK; Gutin P; Iorgulescu JB; Kaley T; DeAngelis L; Pentsova E; Nolan C; Grommes C; Chan T; Bobrow D; Hormigo A; Cross JR; Wu N; Takebe N; Panageas K; Ivy P; Supko JG; Tabar V; Omuro A
    Clin Cancer Res; 2016 Oct; 22(19):4786-4796. PubMed ID: 27154916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma.
    Pan E; Supko JG; Kaley TJ; Butowski NA; Cloughesy T; Jung J; Desideri S; Grossman S; Ye X; Park DM
    J Neurooncol; 2016 Dec; 130(3):571-579. PubMed ID: 27826680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
    Peereboom DM; Ye X; Mikkelsen T; Lesser GJ; Lieberman FS; Robins HI; Ahluwalia MS; Sloan AE; Grossman SA
    Neurosurgery; 2021 Jan; 88(2):246-251. PubMed ID: 33027815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia.
    Diaz-Padilla I; Wilson MK; Clarke BA; Hirte HW; Welch SA; Mackay HJ; Biagi JJ; Reedijk M; Weberpals JI; Fleming GF; Wang L; Liu G; Zhou C; Blattler C; Ivy SP; Oza AM
    Gynecol Oncol; 2015 May; 137(2):216-22. PubMed ID: 25769658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma.
    Yahyanejad S; King H; Iglesias VS; Granton PV; Barbeau LM; van Hoof SJ; Groot AJ; Habets R; Prickaerts J; Chalmers AJ; Eekers DB; Theys J; Short SC; Verhaegen F; Vooijs M
    Oncotarget; 2016 Jul; 7(27):41251-41264. PubMed ID: 27183910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.
    Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS
    Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
    Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
    Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma.
    Saito N; Aoki K; Hirai N; Fujita S; Iwama J; Hiramoto Y; Ishii M; Sato K; Nakayama H; Harashina J; Hayashi M; Izukura H; Kimura H; Ito K; Sakurai T; Yokouchi Y; Oharazeki T; Takahashi K; Iwabuchi S
    Brain Tumor Pathol; 2015 Jul; 32(3):176-83. PubMed ID: 25665548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
    Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
    Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
    Tolcher AW; Messersmith WA; Mikulski SM; Papadopoulos KP; Kwak EL; Gibbon DG; Patnaik A; Falchook GS; Dasari A; Shapiro GI; Boylan JF; Xu ZX; Wang K; Koehler A; Song J; Middleton SA; Deutsch J; Demario M; Kurzrock R; Wheler JJ
    J Clin Oncol; 2012 Jul; 30(19):2348-53. PubMed ID: 22529266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
    Debeb BG; Cohen EN; Boley K; Freiter EM; Li L; Robertson FM; Reuben JM; Cristofanilli M; Buchholz TA; Woodward WA
    Breast Cancer Res Treat; 2012 Jul; 134(2):495-510. PubMed ID: 22547109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Holdhoff M; Ye X; Supko JG; Nabors LB; Desai AS; Walbert T; Lesser GJ; Read WL; Lieberman FS; Lodge MA; Leal J; Fisher JD; Desideri S; Grossman SA; Wahl RL; Schiff D
    Neuro Oncol; 2017 Jun; 19(6):845-852. PubMed ID: 28371832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.
    Omuro A; Beal K; McNeill K; Young RJ; Thomas A; Lin X; Terziev R; Kaley TJ; DeAngelis LM; Daras M; Gavrilovic IT; Mellinghoff I; Diamond EL; McKeown A; Manne M; Caterfino A; Patel K; Bavisotto L; Gorman G; Lamson M; Gutin P; Tabar V; Chakravarty D; Chan TA; Brennan CW; Garrett-Mayer E; Karmali RA; Pentsova E
    J Clin Oncol; 2018 Jun; 36(17):1702-1709. PubMed ID: 29683790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
    Sardesai S; Badawi M; Mrozek E; Morgan E; Phelps M; Stephens J; Wei L; Kassem M; Ling Y; Lustberg M; Stover D; Williams N; Layman R; Reinbolt R; VanDeusen J; Cherian M; Grever M; Carson W; Ramaswamy B; Wesolowski R
    Invest New Drugs; 2020 Oct; 38(5):1400-1410. PubMed ID: 31953695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-myeloma effect of pharmacological inhibition of Notch/gamma-secretase with RO4929097 is mediated by modulation of tumor microenvironment.
    Pisklakova A; Grigson E; Ozerova M; Chen F; Sullivan DM; Nefedova Y
    Cancer Biol Ther; 2016 May; 17(5):477-85. PubMed ID: 26934342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L; Dai G; Yang J; Wu W; Zhang W
    Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma.
    Phuphanich S; Carson KA; Grossman SA; Lesser G; Olson J; Mikkelsen T; Desideri S; Fisher JD;
    Neuro Oncol; 2008 Aug; 10(4):617-23. PubMed ID: 18477765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.